Jun 30, 2020
Gilead to charge $ 2,340 per patient for coronavirus medication
This news has been received from: cvbj.biz
All trademarks, copyrights, videos, photos and logos are owned by respective news sources. News stories, videos and live streams are from trusted sources.
By Michael Erman, Ludwig Burger and Manojna Maddipatla
Jun 29 (.) – Gilead Sciences Inc on Monday set the price of its antiviral for COVID-19, remdesivir, at $ 2,340 per patient for wealthier countries and agreed to send almost all of its supply to the United States over the next three months.
The price is slightly below the $ 2,520 to $ 2,800 range suggested last week by the United States’ Drug Pricing Research Group, the Institute for Clinical and Economic Review (ICER), after British researchers said they found that dexamethasone, a cheap steroid, significantly reduced mortality among seriously ill COVID-19 patients.
Remdesivir may be in high demand because it is one of the only treatments that has been shown to alter the course of COVID-19, after the intravenous drug helped shorten recovery time in hospital in a clinical trial and Obtained emergency use authorization in the United States and full approval in Japan.
For insured United States patients, Gilead said he will charge $ 3,120 for a five-day treatment, or $ 520 per vial. 33% more than the $ 390 per vial that Gilead said he will bill governments in developed countries and patients of Americans in government health programs.
In an open letter, Gilead Chief Executive Daniel O’Day said the price is well below the value it provides, given that early hospital discharges could save about $ 12,000 per patient in the United States.
Patient advocates like Public Citizen argue that the cost should be lower since remdesivir was developed with financial support from the United States government.
Peter Maybarduk, director of Public Citizen’s drug access program, called the price “an offensive display of arrogance and contempt for the public.” Although the drug modestly reduced hospital stays, it has not been shown to reduce deaths in COVID-19 patients.
Gilead also said he agreed to continue to send his supply of remdesivir to the United States Department of Health and Human Services (HHS) and that the agency and states will handle the allocation to hospitals until the end of September.
(Information from Manojna Maddipatla from Bengaluru. Edited in Spanish by Marion Giraldo and Javier López de Lérida)
News Source: cvbj.biz
What are the visas that the US suspends students (and who is affected by the measure) Prensa Libre
The United States Customs and Immigration Office suspends visas for some students. (Free Press Photo: Pixabay)
The United States announced this Monday, July 6, that will suspend visas for foreign students whose classes are transferred to a virtual format due to the COVID-19 pandemic.
The United States Office of Immigration and Customs Enforcement said in a statement that students with F-1 and M-1 visas whose schools operate only online “must leave the country or take other measures, like being transferred to a school with face-to-face instruction. ”
If they do not, students risk expulsion.
According to the new regulations, when students are in a center with a mixed model, they will have to prove that they are enrolled in the maximum number of face-to-face courses to preserve their visa.
The United States – the country with the most deaths from the coronavirus, with more than 130,000 deaths – also suspended until the end of 2020 the delivery of work visas to protect employment.
Many universities and teaching centers will not resume face-to-face classes when the next school year begins in September, at a time when there is still no vaccine against COVID-19 and cases are on the rise due to an increase in infections in the South and the west of the country.